论文部分内容阅读
目的:研究半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞增殖的影响。方法:采用血清药理学方法和MTT法及台盼兰染色法观察半夏泻心方及其配伍药组对体外人胃癌BGC 823细胞的敏感性及生长抑制作用。结果:辛苦组对人胃癌BGC 823细胞的生长抑制作用最强,显著高于辛开组、苦降组、辛甘组、苦甘组、甘补组(P<0.05)。结论:半夏泻心方中对BGC 823细胞增殖起主要抑制作用的药组为辛开、苦降的配伍形式。辛开、苦降配伍后(辛苦)有显著的协同增效趋势,而其他配伍药群可能存在拮抗作用。提示辛开苦降法可能是中医药防治胃癌的治则治法之一。
Objective: To study the effect of Banxia Xiexin Formula and its combination on the proliferation of human gastric cancer BGC 823 cells in vitro. METHODS: Serum pharmacology, MTT assay, and trypan blue staining were used to observe the sensitivity and growth inhibitory effect of Banxia Xiexin Recipe and its combination drug group on human gastric cancer BGC 823 cells in vitro. Results: The hardest group had the strongest inhibitory effect on the growth of human gastric cancer BGC 823 cells, which was significantly higher than that of Xinkai group, bitter drop group, Xingan group, bitter sweet group and Ganbu group (P<0.05). Conclusion: The drug group that mainly inhibits the proliferation of BGC 823 cells in Banxia Xiexin Recipe is a compatible form of Xinkai and bitter drop. After the combination of Xinkai and bitter drops (hard work), there is a significant synergistic trend, while other compatible drug groups may have antagonistic effects. It is suggested that the Xinkaibandi method may be one of the treatment methods for the prevention and treatment of gastric cancer by Chinese medicine.